The changing shape of type 2 diabetes CME

MedGenMed Medscape General Medicine

Volumn 10, Issue 6, 2008, Pages

  Brunton, Stephen A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; NOVOLOGI MIX 70 30; ORAL ANTIDIABETIC AGENT; RIMONABANT; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ADD ON THERAPY; AGE DISTRIBUTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEFECATION URGENCY; DIABETES CONTROL; DIET; DRUG TREATMENT FAILURE; FECES INCONTINENCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFORMATION RETRIEVAL; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MEDLINE; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; TACHYCARDIA; VASCULAR DISEASE; WEIGHT GAIN; AGE; LIFESTYLE; PATHOPHYSIOLOGY;

AGE FACTORS; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; OBESITY;

EID: 45749084498     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Misra A, Misra R, Wijesuriya. M, Banerjee D. The metabolic syndrome in South Asians: Continuing escalation & possible solutions. Indian J Med Res. 2007; 125:345-354.
3. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genetics. 1962;14:353-362.
4. Speakman JR. Thrifty genes for obesity and the metabolic syndrome-time to call off the search? Diab Vasc Dis Res. 2006;3:7-11.
5. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29:2114-2116.
6. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-1890.
7. Centers for Disease Control. National Diabetes Fact Sheet. United States. 2005. Available at: http:/www.cdc.gov/diabetes/pubs/pdf/ ndfs_2005.pdf Accessed May 30, 2007.
8. Hoy WE, Kondalsamy-Chennakesavan S, Wang Z, et al; AusDiab Study Group. Quantifying the excess risk for proteinuria, hypertension and diabetes in Australian Aborigines: comparison of profiles in three remote communities in the Northern Territory with those in the AusDiab study. Aust N Z J Public Health. 2007;31:177-183.
9. Harris MI. Summary. In: Diabetes in America. 2nd ed. Washington, DC. Government Printing Office. NIH publication 1995;5-1468:1-14. Available at: http://diabetes.niddk.nih.gov/dm/pubs/america/contents.htm. Accessed May 14, 2008.
10. Zinman B. Type 2 diabetes mellitus: magnitude of the problem and failure to achieve glycemic control. Endocrinol Metab Clin North Am. 2006;35(Suppl 1):3-5.
11. Day C. Metabolic syndrome, or what you will: Definitions and epidemiology. Diab Vasc Dis Res. 2007;4:32-38.
12. Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc. 2007;66:82-95.
13. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. Metab Syndr Relat Disord. 2004;2:105-113.
14. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab. 2000;85:2970-2973.
15. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dandona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr. 2004;80:51-57.
16. Dandona P, Mohanty P, Hamouda W, et al. Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma ortho-tyrosine and meta-tyrosine concentrations. J Clin Endocrinol Metab. 2001;86:2899-2902.
17. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
18. Wu Y. Overweight and obesity in China. BMJ. 2006;333:362-363.
19. Zhou B-F. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases - Report for meta-analysis of prospective studies on optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci. 2002;15:245-252.
20. Foreyt JP. Cultural competence in the prevention and treatment of obesity: Latino Americans. Permanente J. 2003;7:42-45.
21. Mazur RE, Marquis GS, Jensen HH. Diet and food insufficiency among Hispanic youths: acculturation and socioeconomic factors in the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2003;78:1120-1127.
22. Musaiger AO, al-Roomi KA. Prevalence of risk factors for cardiovascular diseases among men and women in an Arab Gulf community. Nutr Health. 1997;11:149-157.
23. Rocchini AP. Childhood obesity and a diabetes epidemic. N Engl J Med. 2002;346:854-855.
24. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
25. Weinstock RS. Treating type 2 diabetes mellitus: a growing epidemic. Mayo Clin Proc. 2003;78:411-413.
26. Centers for Disease Control. National Diabetes Surveillance System. 2007. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/ tnumage.htm Accessed May 30, 2007.
27. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700.
28. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369:1823-1831.
29. Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20:844-847.
30. Dominiczak MH. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin Chem Lab Med. 2003;41:1266-1278.
31. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114-1120.
32. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.
33. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
34. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
35. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461-465.
36. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617-621.
37. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
38. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5:919-931.
39. Rimonabard Regulatory Update in the United States. Availablp at: http://en.sanofi-aventis.com/press/ppc_17004.asp#3 Accessed July 17, 2007.
40. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
41. Lindström J, Ilanne-Parikka P, Peltonen M, et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679.
42. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
43. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
44. Jellinger PS, Davidson JA, Blonde L, et al; ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260-268.
45. The Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
46. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
47. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
48. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
49. Nathan DM. Finding new treatments for diabetes - how many, how fast... how good? N Engl J Med. 2007;356:437-440.
50. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
51. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007;357:28-38.
52. FDA. Information for healthcare professionals on rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm Accessed April 8, 2008.
53. Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 diabetes? Neth J Med. 2007;65:60-64.
54. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care. 2007;13(Suppl 2):S47-54.
55. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
56. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled tri al. Diabetes Care. 2004;27:1335-1342.
57. Levy P. Insulin analogues or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Med Gen Med. 2007;9:12.
58. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des. 2001;7:1303-1325.
59. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418-427.
60. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629.
61. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
62. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569-1581.
63. Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less wtaight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27:279-285.
64. Heinemann L. Overcoming obstacles: new management options. Eur J Endo. 2004;151:T23-27.
65. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55:62-68.
66. Korytkowski M, Bell D, Jacobsen C, Suwannasari R;. FlexPen Study Team A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848.
67. Philips P. Type 2 diabetes - failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud. 2005;2:35-39.
68. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.